Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma

Publication

Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma

Journal Paper/Review - Feb 27, 2007

Hau P, Koch H, Jauch T, Schuth J, Rieckmann P, Brenner A, Rauch M, Rudolph R, Bauer B, Marg E, Hundsberger Thomas, Koch D, Bogdahn U

Citation

Hau P, Koch H, Jauch T, Schuth J, Rieckmann P, Brenner A, Rauch M, Rudolph R, Bauer B, Marg E, Hundsberger T, Koch D, Bogdahn U. Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma. Neurology 2007; 68:688-90.

Type

Journal Paper/Review (English)

Journal

Neurology 2007; 68

Publication Date

Feb 27, 2007

Issn Electronic

1526-632X

Pages

688-90

Brief description/objective

We surveyed neuro-oncologists regarding patients treated with temozolomide for at least 12 cycles or 12 months. Patients receiving first-line temozolomide for a median 13 cycles had a median progression-free survival (PFS) of 14 months. Patients with recurrent disease receiving a median 14 cycles had a median PFS of 15.5 months. A small percentage of patients experienced grade III to IV toxicity. These results suggest that long-term treatment with temozolomide is feasible and well tolerated.